BEDFORD, N.H., Oct. 2, 2024 /PRNewswire/ -- Ambetter from NH Healthy Families, a product offered by a Centene Corporation (NYSE:CNC) company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, announced today that it will offer a variety of affordable health insurance plans statewide in New Hampshire for plan year 2025. Open enrollment for the Health Insurance Marketplace for New Hampshire runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15 for coverage starting Jan. 1, 2025.
"We are deeply committed to delivering healthcare that is affordable and available to ensure that individuals, families and communities can access the care they need," said NH Healthy Families interim Plan President and Chief Executive Officer, Christopher Cameron. "With Ambetter from NH Healthy Families' diverse array of plan options based on budget and need, more people can find the coverage that works for them."
Ambetter from NH Healthy Families offers its members access to quality care, convenient services and valuable rewards. The 2025 benefits and offerings include:
New Hampshire residents interested in learning more about Ambetter from NH Healthy Families or enrolling in a health plan during the open enrollment period may visit ambetterhealth.com/en/nh.
About Ambetter from NH Healthy Families
Ambetter from NH Healthy Families serves under-insured and uninsured populations through the federal Health Insurance Marketplace. Ambetter from NH Healthy Families is underwritten by Celtic Insurance Company, which is a Qualified Health Plan issuer in New Hampshire. For more information visit ambetterhealth.com/en/nh. This is a solicitation for insurance. For information on your right to receive an Ambetter from NH Healthy Families plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$33.26 |
Daily Change: | -0.82 -2.41 |
Daily Volume: | 14,543,229 |
Market Cap: | US$16.330B |
July 29, 2025 July 25, 2025 April 25, 2025 February 24, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load